@now_arsenaI Think as a growth strategy, Arsenal should encourage their loyal former players to become managers. You always have a soft spot for your former club... Get young players from the academy get nurtured by someone who knows the philosophy and even the trade deals will favour you.
Novo launches Wegovy subscription plans with a 3, 6, and 12-month options with predictable flat pricing for cash payers.
Longer plans deliver bigger savings (up to $1,200/year injection, $600/year pill).
No price changes even when moving doses.
Starts today via telehealth partners (Ro, WeightWatchers, LifeMD, Sesame, Hims & Hers).
Targets adherence as ~65% dropout rate within first year for GLP-1s
Strategic context:
Helps patients โstart but stay on therapyโ amid GI side effects and access issues.
Comes as pill sees explosive uptake but faces Lilly oral competitor later this year.
Novo not yet on its own NovoCare pharmacy but evaluating expansion.
Patient retention and competitive moat focus for $NVO.
Stock below key EMA's on the chart.
This just goes to show how flawed our thinking is. Instead of this scarecrow that cost millions, we should have planted trees at a fraction of this thing. #Nairobi#IWD2019#BalancedForBetter#FridayThoughts